Fri May 02 2025 21:10:02 GMT+0000 (Coordinated Universal Time)

Pheiron and Ribo have successfully achieved their first two milestones, advancing AI-assisted drug discovery and development for siRNA therapeutics.

Published September 17, 2024

Stakeholders lack critical evidence on whether their drug target will work in humans before trialing for it, and they lack tools to use insights on target biology to optimize clinical positioning. Human evidence from large populations offers critical insights to navigate and de-risk R&D: ensure target safety and efficacy at the earliest stages and align target biology with the right clinical phenotypes benefitting from target modulation.